Patents by Inventor Tien T. Duong

Tien T. Duong has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Bicyclic compounds having activity at the CXCR4 receptor
    Patent number: 8193203
    Abstract: A compound represented by the structural formula: Therapeutic methods, compositions, and medicaments related thereto are also disclosed.
    Type: Grant
    Filed: May 18, 2009
    Date of Patent: June 5, 2012
    Assignee: Allergan, Inc.
    Inventors: Richard L. Beard, Tien T. Duong, Thong H. Vu, Vidyasagar Vuligonda, John E. Donello, Michael E. Garst, Gerard A. Rodrigues
  • Indole compounds having sphingosine-1-phosphate (S1P) receptor antagonist
    Patent number: 8097644
    Abstract: The present invention provides novel compounds having the following general formula I wherein: A, B, X, Y, R1, R2, R3, R4, n, o and p are as defined in the specification. Such compounds are useful for treating a disease or condition selected from the group consisting of glaucoma, dry eye, angiogenesis, cardiovascular conditions or diseases and wound healing.
    Type: Grant
    Filed: March 23, 2007
    Date of Patent: January 17, 2012
    Assignee: Allergan, Inc.
    Inventors: Richard L. Beard, John E. Donello, Haiqing Yuan, Vidyasagar Vuligonda, Tien T. Duong
  • BICYCLIC COMPOUNDS HAVING ACTIVITY AT THE CXCR4 RECEPTOR
    Publication number: 20090312305
    Abstract: A compound represented by the structural formula: Therapeutic methods, compositions, and medicaments related thereto are also disclosed.
    Type: Application
    Filed: May 18, 2009
    Publication date: December 17, 2009
    Applicant: ALLERGAN, INC.
    Inventors: Richard L. Beard, Tien T. Duong, Thong H. Vu, Vidyasagar Voligonda, John E. Donello, Michael E. Garst, Gerard A. Rodrigues
  • Indole Compounds having sphingosine-1-phosphate (S1P) receptor antagonist
    Publication number: 20070232682
    Abstract: The present invention provides novel compounds having the following general formula I wherein: A, B, X, Y, R1, R2, R3, R4, n, o and p are as defined in the specification. Such compounds are useful for treating a disease or condition selected from the group consisting of glaucoma, dry eye, angiogenesis, cardiovascular conditions or diseases and wound healing.
    Type: Application
    Filed: March 23, 2007
    Publication date: October 4, 2007
    Applicant: ALLERGAN, INC.
    Inventors: Richard L. Beard, John E. Donello, Haiqing Yuan, Vidyasagar Vuligonda, Tien T. Duong
  • 7-[(7-Alkoxy)-chrom-3-en-6-yl]-heptatrienoic acid and 7-[(3-alkoxy)-5,6-dihydronaphthalen-2-yl]-heptatrienoic acid derivatives having serum glucose reducing activity
    Patent number: 6887896
    Abstract: Compounds of the formula where the variations have the meaning defined in the specification are capable of reducing serum glucose levels in diabetic mammals without the undesirable side effects of transiently increasing triglyceride levels and reducing serum thyroxine levels.
    Type: Grant
    Filed: October 29, 2003
    Date of Patent: May 3, 2005
    Assignee: Allergan, Inc.
    Inventors: Richard L. Beard, Tien T. Duong, Janet A. Takeuchi, Ling Li, Kwok Yin Tsang, Xiaoxia Liu, Jayasree Vasudevan, Liming Wang, Santosh C. Sinha, Haiqing Yuan, Roshantha A. Chandraratna
  • Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
    Patent number: 6818775
    Abstract: Compounds of the formula where the symbols have the meaning described in the application, have retinoid-like or retinoid antagonist-like biological activity.
    Type: Grant
    Filed: December 9, 2003
    Date of Patent: November 16, 2004
    Assignee: Allergan, Inc.
    Inventors: Alan T. Johnson, Min Teng, Vidyasagar Vuligonda, Richard L. Beard, Samuel J. Gillett, Tien T. Duong, Roshantha A. Chandraratna
  • Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
    Publication number: 20040127469
    Abstract: Compounds of the formula 1
    Type: Application
    Filed: December 9, 2003
    Publication date: July 1, 2004
    Inventors: Alan T. Johnson, Min Teng, Vidyasagar Vuligonda, Richard L. Beard, Samuel J. Gillett, Tien T. Duong, Roshantha A. Chandraratna
  • Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
    Patent number: 6720425
    Abstract: Compounds of the formula where the symbols have the meaning described in the application, have retinoid-like or retinoid antagonist-like biological activity.
    Type: Grant
    Filed: December 9, 2002
    Date of Patent: April 13, 2004
    Assignee: Allergan, Inc.
    Inventors: Alan T. Johnson, Min Teng, Vidyasagar Vuligonda, Richard L. Beard, Samuel J. Gillett, Tien T. Duong, Roshantha A. Chandraratna
  • Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
    Patent number: 6653483
    Abstract: Compounds of the formula where the symbols have the meaning described in the application, have retinoid-like or retinoid antagonist-like biological activity.
    Type: Grant
    Filed: April 17, 2000
    Date of Patent: November 25, 2003
    Inventors: Alan T. Johnson, Min Teng, Vidyasagar Vuligonda, Richard L. Beard, Samuel J. Gillett, Tien T. Duong, Roshantha A. Chandraratna
  • Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
    Publication number: 20030187235
    Abstract: Compounds of the formula 1
    Type: Application
    Filed: December 9, 2002
    Publication date: October 2, 2003
    Inventors: Alan T. Johnson, Min Teng, Vidyasagar Vuligonda, Richard L. Beard, Samuel J. Gillett, Tien T. Duong, Roshantha A. Chandraratna
  • TRICYCLO[6.2.202,7]DODECA-2(7),3,5-TRIEN-4-CARBONYLAMINO-PHENYL AND TRICYCLO[6.2.202,7]DODECA-2(7),3,5-TRIEN-4-CARBONYLAMINO-HETEROARYL AND RELATED COMPOUNDS HAVING RAR&agr; RECEPTOR SELECTIVE BIOLOGICAL ACTIVITY
    Patent number: 6620963
    Abstract: Compounds of the formula where the variables have the meaning defined in the specification, which bind specifically or selectively to to RAR&agr; retinoid receptors.
    Type: Grant
    Filed: September 19, 2002
    Date of Patent: September 16, 2003
    Assignee: Allergan, Inc.
    Inventors: Tien T. Duong, Richard Beard, Roshantha A. Chandraratna
  • Methods of treatment with compounds having RAR&agr; receptor specific or selective activity
    Patent number: 6610744
    Abstract: Retinoid compounds which act specifically or selectively on RAR&agr; receptor subtypes in preference over RAR&bgr; and RAR&Ggr; receptor subtypes, posses desirable pharmaceutical properties associated with retinoids, and are particularly suitable for treatment of tumors, such as acute monocytic leukemia, cervical carcinoma, myeloma, ovarian carcinomas and head and neck carcinomas, without having one or more undesirable side effects of retinoids, such as inducement of weight loss, mucocutaneous toxicity, skin irritation and teratogenecity.
    Type: Grant
    Filed: November 29, 2001
    Date of Patent: August 26, 2003
    Assignee: Allergan, Inc.
    Inventors: Min Teng, Tien T. Duong, Roshantha A. Chandraratna
  • Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
    Patent number: 6555690
    Abstract: Compounds of the formula where the symbols have the meaning described in the application, have retinoid-like or retinoid antagonist-like biological activity.
    Type: Grant
    Filed: May 8, 2002
    Date of Patent: April 29, 2003
    Assignee: Allergan, Inc.
    Inventors: Alan T. Johnson, Min Teng, Vidyasagar Vuligonda, Richard L. Beard, Samuel J. Gillett, Tien T. Duong, Roshantha A. Chandraratna
  • Methods of treatment with compounds having RAR&agr; receptor specific or selective activity
    Patent number: 6534544
    Abstract: Retinoid compounds which act specifically or selectively on RAR&agr; receptor subtypes in preference over RAR&bgr; and RAR&Ggr; receptor subtypes, possess desirable pharmaceutical properties associated with retinoids, and are particularly suitable for treatment of tumors, such as acute monocytic leukemia, cervical carcinoma, myeloma, ovarian carcinomas and head and neck carcinomas, without having one or more undesirable side effects of retinoids, such as inducement of weight loss, mucocutaneous toxicity, skin irritation and teratogenecity.
    Type: Grant
    Filed: July 9, 1999
    Date of Patent: March 18, 2003
    Assignee: Allergan Sales, Inc.
    Inventors: Min Teng, Tien T. Duong, Roshantha A. Chandraratna
  • Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
    Patent number: 6521624
    Abstract: Aryl-substituted and aryl and (3-oxo-1-propenly)-substituted benzopyran, benzothiopyran, 1,2-dihydroquinoline, and 5,6-dihydronaphthalene derivatives have retinoid negative hormone and/or antagonist-like biological activities. The invented RAR antagonists can be administered to mammals, including humans, for the purpose of preventing or diminishing action of RAR agonists on the bound receptor sites. Specifically, the RAR agonists are administered or coadministered with retinoid drugs to prevent or ameliorate toxicity or side effects caused by retinoids or vitamin A or vitamin A precursors. The retinoid negative hormones can be used to potentiate the activities of other retinoids and nuclear receptor agonists. For example, the retinoid negative hormone called AGN 193109 effectively increased the effectiveness of other retinoids and steroid hormones in in vitro transactivation assays. Additionally, transactivation assays can be used to identify compounds having negative hormone activity.
    Type: Grant
    Filed: March 23, 2000
    Date of Patent: February 18, 2003
    Assignee: Allergan, Inc.
    Inventors: Elliott S. Klein, Alan T. Johnson, Andrew M. Standeven, Richard L. Beard, Samuel J. Gillett, Tien T. Duong, Sunil Nagpal, Vidyasagar Vuligonda, Min Teng, Roshantha A. Chandraratna
  • Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
    Publication number: 20020173631
    Abstract: Compounds of the formula 1
    Type: Application
    Filed: May 8, 2002
    Publication date: November 21, 2002
    Inventors: Alan T. Johnson, Min Teng, Vidyasagar Vuligonda, Richard L. Beard, Samuel J. Gillett, Tien T. Duong, Roshantha A. Chandraratna
  • Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
    Publication number: 20020156054
    Abstract: Aryl-substituted and aryl and (3-oxo-1-propenly)-substituted benzopyran, benzothiopyran, 1,2-dihydroquinoline, and 5,6-dihydronaphthalene derivatives have retinoid negative hormone and/or antagonist-like biological activities. The invented RAR antagonists can be administered to mammals, including humans, for the purpose of preventing or diminishing action of RAR agonists on the bound receptor sites. Specifically, the RAR agonists are administered or coadministered with retinoid drugs to prevent or ameliorate toxicity or side effects caused by retinoids or vitamin A or vitamin A precursors. The retinoid negative hormones can be used to potentiate the activities of other retinoids and nuclear receptor agonists. For example, the retinoid negative hormone called AGN 193109 effectively increased the effectiveness of other retinoids and steroid hormones in in vitro transactivation assays. Additionally, transactivation assays can be used to identify compounds having negative hormone activity.
    Type: Application
    Filed: March 28, 2001
    Publication date: October 24, 2002
    Inventors: Elliott S. Klein, Alan T. Johnson, Andrew M. Standeven, Richard L. Beard, Samuel J. Gillett, Tien T. Duong, Sunil Nagpal, Vidyasagar Vuligonda, Min Teng, Roshantha A. Chandraratna
  • Synthesis and use of retinoid compounds having negative hormone and/or anatgonist activities
    Patent number: 6469028
    Abstract: Aryl-substituted and aryl and (3-oxo-1-propenly)-substituted benzopyran, benzothiopyran, 1,2-dihydroquinoline, and 5,6-dihydronaphthalene derivatives have retinoid negative hormone and/or antagonist-like biological activities. The invented RAR antagonists can be administered to mammals, including humans, for the purpose of preventing or diminishing action of RAR agonists on the bound receptor sites. Specifically, the RAR agonists are administered or coadministered with retinoid drugs to prevent or ameliorate toxicity or side effects caused by retinoids or vitamin A or vitamin A precursors. The retinoid negative hormones can be used to potentiate the activities of other retinoids and nuclear receptor agonists. For example, the retinoid negative hormone called AGN 193109 effectively increased the effectiveness of other retinoids and steroid hormones in in vitro transactivation assays. Additionally, transactivation assays can be used to identify compounds having negative hormone activity.
    Type: Grant
    Filed: March 28, 2001
    Date of Patent: October 22, 2002
    Assignee: Allergan, Inc.
    Inventors: Elliott S. Klein, Alan T. Johnson, Andrew M. Standeven, Richard L. Beard, Samuel J. Gillett, Tien T. Duong, Sunil Nagpal, Vidyasagar Vuligonda, Min Teng, Roshantha A. Chandraratna
  • Substituted aryl or heteroarylamides having retinoid-like biological activity
    Patent number: 6437129
    Abstract: Compounds of the formula wherein X, L, Y, A, B, W, R1, m, p and r are defined above.
    Type: Grant
    Filed: October 16, 2001
    Date of Patent: August 20, 2002
    Assignee: Allergan Sales, LLC
    Inventors: Min Teng, Tien T. Duong, Roshantha A. Chandraratna
  • Substituted aryl or heteroarylamides having retinoid-like biological activity
    Publication number: 20020091262
    Abstract: Compounds of the formula 1
    Type: Application
    Filed: October 16, 2001
    Publication date: July 11, 2002
    Applicant: Allergan
    Inventors: Min Teng, Tien T. Duong, Roshantha A. Chandraratna